Nevertheless, when adjusting for immortal time bias, this survival advantage did not reach statistical significance even though a tendency for improved survival was maintained during the period between 6 months and 4 years after ICI start.
← all excerpts
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study.
1
—
—